Loading...

Jcancom's Recent CancerCompass Activity

  • Jcancom has replied to a post on the message board

    I have a fondness for PMID:25579853. The idea is quite extreme, though it might possibly work. When I was reading it just now this popped out "Such evidence may explain why introduction of healthy mitochondria into cancer cell cytoplasm halts carcinogenesis". Didn't a poster on our thread recently note that a phase 1 clinical trial has been published in which mitochondria are transfered to cells for therapeutic effe...

    May 21 at 2:45 AM view post
    • Jcancom has replied to a post on the message board

      Don't understand. They go to the trouble and make a really good nM drug that looks very impressive and then a toxic drug is reformulated and it is even better and less toxic than CB-839. Why don't formulate CB-839 into NPs to make safer and more effective? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018752/pdf/pnas.201611406.pdf

      May 21 at 12:53 AM view post
      • Jcancom has replied to a post on the message board

        Hey, you're right I thought I saw an HK-2 drug somewhere; now it has vanished. THAT would be a very very interesting combo to see what metabolics could do. On their presentations, CD-839 by itself does not look as though it is doing very much much, then they add in an mTOR and that pretty much stopped tumor growth for what seems forever. I would though like to see what happens as you said if they went right in their ...

        May 20 at 8:33 PM view post
        • Jcancom has replied to a post on the message board

          Calithera's share price has increased by 5 times since the start of this ------- year. http://www.calithera.com/wp-content/uploads/2017/03/03.2017-Keystone-poster-Emberley-2017.pdf Not difficult to understand why when you consider that it has programs in triple negative breast, colorectal, RCC, just announced a deal to start up in lung and melanoma for CB-839. Metabolics attack such a fundamental component of cance...

          May 19 at 11:04 PM view post
          • Jcancom has replied to a post on the message board

            Yet, more metabolic medicine. http://ir.celgene.com/releasedetail.cfm?releaseid=1015105

            May 19 at 9:26 PM view post
            • Jcancom has replied to a post on the message board

              Thank you critic, looks like there is even more good news: http://cornerstonepharma.com.bh-in-2.webhostbox.net/images/press-releases/Cornerstone_Press_Release_Announcement_Initiation_Pivotal_Trials_March_2017.pdf I am starting to have a very positive feeling about metabolic medicine. There now appear to be a whole network of metabolic drugs in the pipe. Interesting things can happen when entire pathways are targete...

              May 19 at 2:16 AM view post
              • Jcancom has replied to a post on the message board

                The potential for a new era in natural organic treatment or however one might want to express it is enormous.  Perhaps cancer therapy could move entirely away from introducing potentially dangerous chemicals into the body with therapeutic intent, and instead supply autologous mitcohondriar which are probably safe.  The potential of the metabolic approach in cancer which we have pursued for years on thread ...

                May 14 at 4:29 PM view post
                • Jcancom has replied to a post on the message board

                  PMID:28342934 "Once transplanted the mitochondria increase total tissue ATP content and ATP synthesis. This increase in high energy acts rapidly, as early as 10 minutes following delivery of the mitochondria to the heart, to enhance cardiac function ... At 10 min to 1 h following transplantation the transplanted mitochondria are internalized ... Once internalized the transplanted mitochondria further increase cardio...

                  May 14 at 4:14 PM view post
                  • Jcancom has replied to a post on the message board

                    Mitochondria organelle transplantation: introduction of normal epithelial mitochondria into human cancer cells inhibits proliferation and increases drug sensitivity PMID:23080556 "In conclusion, the introduction of normal mammary mitochondria into human breast cancer cells inhibits cancer cell proliferation and increases the sensitivity of the MCF-7 human breast cancer cell line to doxorubicin, Abraxane, and carbo...

                    May 14 at 4:04 PM view post
                    • Jcancom has replied to a post on the message board

                      I have been waiting for this one! PMID:28342934 Mitochondrial Replacement!Things are starting to warm up!  "other groups have shown that mitochondrial transplantation can be used to enhance drug sensitivity in human breast cancer cells"  Very interesting possibilities of changing mitochondria and perhaps other metabolic pathways. "Our result showing induction of EMT in mtDNA-reduced MCF10A and MCF7 cells i...

                      May 14 at 5:26 AM view post
                      Loading...
                      Load more activity
                      Loading more activity

                      About Jcancom

                      Jcancom has not shared any information about themselves. Send them a message to tell them you'd like to find out more about them or add them as a friend.

                      We care about your feedback. Let us know how we can improve your CancerCompass experience.